Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical experience with aurora kinase inhibitors: a review.

Literature DB >> 19684075

Clinical experience with aurora kinase inhibitors: a review.

David S Boss¹, Jos H Beijnen, Jan H M Schellens.

Abstract

The aurora kinase family of serine/threonine kinases comprises three members, designated auroras A, B, and C. Auroras A and B are essential components of the mitotic pathway, ensuring proper chromosome assembly, formation of the mitotic spindle, and cytokinesis. The role of aurora C is less clear. Overexpression of aurora A and B has been observed in several tumor types, and has been linked with a poor prognosis of cancer patients. Several small molecules targeting aurora kinases A and B or both have been evaluated preclinically and in early phase I trials. In this review we aim to summarize the most recent advances in the development of aurora kinase inhibitors, with a focus on the clinical data.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19684075 DOI： 10.1634/theoncologist.2009-0019

Source DB: PubMed Journal: Oncologist ISSN： 1083-7159

Keyword Cloud
Cited

39 in total

1. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

Authors: Gary K Schwartz; Richard D Carvajal; Rachel Midgley; Scott J Rodig; Paul K Stockman; Ozlem Ataman; David Wilson; Shampa Das; Geoffrey I Shapiro
Journal: Invest New Drugs Date: 2012-06-02 Impact factor: 3.850

2. Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.

Authors: Kleiton Silva Borges; Angel Maurício Castro-Gamero; Daniel Antunes Moreno; Vanessa da Silva Silveira; Maria Sol Brassesco; Rosane Gomes de Paula Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal: J Cancer Res Clin Oncol Date: 2011-12-09 Impact factor: 4.553

Review 3. Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors: Muneera Al-Hussaini; John F DiPersio
Journal: Expert Rev Hematol Date: 2014-08 Impact factor: 2.929

4. Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer.

Authors: Yun Feng; Hongliang Liu; Bensong Duan; Zhensheng Liu; James Abbruzzese; Kyle M Walsh; Xuefeng Zhang; Qingyi Wei
Journal: Carcinogenesis Date: 2019-06-10 Impact factor: 4.944

5. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Authors: Matthew P Martin; Yunting Luo; Roberta Pireddu; Hua Yang; Harsukh Gevariya; Harshani R Lawrence; Sevil Ozcan; Jin-Yi Zhu; Robert Kendig; Mercedes Rodriguez; Roy Elias; Jin Q Cheng; Saïd M Sebti; Ernst Schonbrunn; Nicholas J Lawrence
Journal: J Med Chem Date: 2012-08-30 Impact factor: 7.446

6. Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.

Authors: Laura W Goff; Nilofer S Azad; Stacey Stein; Jennifer G Whisenant; Tatsuki Koyama; Ulka Vaishampayan; Howard Hochster; Roisin Connolly; Amy Weise; Patricia M LoRusso; Safia N Salaria; Wael El-Rifai; Jordan D Berlin
Journal: Invest New Drugs Date: 2018-09-06 Impact factor: 3.850

7. Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.

Authors: Lifang Xie; Michelle Kassner; Ruben M Munoz; Qiang Q Que; Jeff Kiefer; Yu Zhao; Spyro Mousses; Hongwei H Yin; Daniel D Von Hoff; Haiyong Han
Journal: Biochem Pharmacol Date: 2011-11-15 Impact factor: 5.858